AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

AC Immune S.A.NASDAQ: ACIU

Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025

Stock-based compensation outflow shrinks to CHF 0

Q4 FY2025 stock-based compensation was CHF 0, compared with CHF 967K a year earlier. Trailing-twelve-month stock-based compensation was CHF 2.68M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 20.0 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near CHF 0 or moves back toward the trailing-twelve-month quarterly average of CHF 669.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 0— QoQ
Last fiscal yearDec 2025
CHF 0-100.0% YoY
LTMDec 2025
CHF 2.68M-42.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CHF · from the cash flow

Latest · FY2025
0 CHF
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.8% is the 6th highest of 9, against a peer median of -15.5%.
  • Stock-based compensation amounts to 75.0% of revenue for ACIU, versus a peer median of 1385.0%.
ACIU Competitors
Stock-Based Compensation for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
ANNXAnnexon, Inc.LTM Mar 2026$15.5M USD-21.9%-3.9%—
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
Peer median (excluding ACIU) —-15.5%+6.4%1385.0%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.